Mechanisms and biological consequences of the nuclear receptor CAR activation
Mechanisms and biological consequences of the nuclear receptor CAR activation
批准号:
8336594
负责人:
MASAHIKO NEGISHI
金额:
$334.72万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AffectAndrostanesApoptosisBindingBiologicalCell DeathCell NucleusCell ProliferationCholecalciferolCholestasisChronic DiseaseCytochromesDefense MechanismsDevelopmentDiabetes MellitusDiseaseDisease susceptibilityDrug InteractionsEnvironmental ExposureEnzymesExcretory functionExposure toGADD45GADD45 proteinGene ExpressionGenesGenetic TranscriptionGlucoseGrowth FactorHealthHepaticHepatocyteHomeostasisHumanInjuryInsulinInvestigationLiverMAP2K1 geneMAPK14 geneMAPK3 geneMAPK8 geneMediatingMetabolismMolecularMusNuclearNuclear ReceptorsOrganismOrphanOsteomalaciaPathway interactionsPharmaceutical PreparationsPhenobarbitalPhosphorylationPhysiologicalPituitary GlandPrimary carcinoma of the liver cellsProliferatingProtein Phosphatase 2A Regulatory Subunit PR53Protein phosphataseReceptor ActivationRodentSignal TransductionSpecificitySteroidsSystemTherapeuticThreonineThyroid GlandTranscriptional ActivationXenobiotic MetabolismXenobioticscell motilityfatty acid metabolismmemberoval cellpostnatalpregnane X receptorpreventprogenitorreceptorresponsesulfotransferasetranscription factortumor
中文摘要
CAR激活机制:这个系统的独特之处在于,外源生物不会直接与CAR结合来激活它。我们先前确定内源性CAR的苏氨酸48在小鼠原代肝细胞中被磷酸化,苯巴比妥治疗使该苏氨酸去磷酸化,激活CAR并将其移位到细胞核中。我们现在已经确定蛋白磷酸酶2A是使CAR的苏氨酸48去磷酸化的酶。此外,激活的C-激酶受体1(RACK1)被认为是激活PP2A核心酶使CAR的苏氨酸48去磷酸化的重要调节亚基。我们还将生长因子-MEK1/2-ERK1/2通路定义为一种抑制苏氨酸48去磷酸化从而抑制CAR激活的细胞信号机制。激活的P-ERK1/2直接与磷酸化的CAR相互作用,阻止PP2A与CAR相互作用并使苏氨酸48去磷酸化。苯巴比妥治疗导致P-ERK1/2失活,并使PP2A能够使小鼠原代肝细胞中的苏氨酸48去磷酸化。我们的研究已经将这种去磷酸化定义为CAR激活和功能的主要调节因子。
异源生物信号串扰机制:在被外源生物激活后,CAR对基因的调控是不同的,赋予了CAR调控的基因表达的特异性。CAR通过与细胞信号的串扰获得这种特异性。我们已经确定了多种内源性细胞信号是CAR激活和功能的基本调节因子:垂体因子、p38信号、SGK2信号和早期反应因子GADD45(生长停滞和DNA损伤诱导45)。鉴于这些发现,我们正在研究这些信号调节CAR激活和功能的分子机制。
CAR介导的疾病:慢性药物治疗,如苯巴比妥,已知会激活CAR并导致啮齿类动物的肝细胞癌(HCC)。我们现在已经将GADD45确定为苯巴比妥促进肝癌发展的CAR靶点:CAR与GADD45蛋白相互作用,这种相互作用抑制JNK1的磷酸化,从而抑制细胞凋亡,并可能促进肿瘤的发生。3,5-二乙氧基-1,4-二氢氯仿(DDC)治疗可导致严重的肝损伤和出生后肝祖细胞的增殖。利用CAR KO小鼠,我们已经确定DDC激活CAR,这种激活对于肝损伤和卵圆细胞增殖的发展是必不可少的。
英文摘要
CAR activation mechanism: What is unique about this system is the fact that xenobiotics do not directly bind to CAR to activate it. We previously determined that threonine 48 of endogenous CAR is phosphorylated in mouse primary hepatocytes and that phenobarbital treatment de-phosphorylates this threonine, activating CAR and translocating it into the nucleus. We have now identified protein phosphatase 2A as the enzyme that de-phosphorylates threonine 48 of CAR. Moreover, receptor for activated C-kinase1 (RACK1) was characterized as the essential regulatory subunit that activates the PP2A core enzyme to de-phosphorylate threonine 48 of CAR. We have also defined the growth factor-MEK1/2-ERK1/2 pathway as a cell signaling mechanism that represses de-phosphorylation of threonine 48, thus repressing CAR activation. Activated P-ERK1/2 directly interacts with phosphorylated CAR and prevents PP2A from interacting with CAR and de-phosphorylating threonine 48. Phenobarbital treatment results in inactivation of P-ERK1/2 and enables PP2A to de-phosphorylate threonine 48 in mouse primary hepatocytes. Our investigations have defined this de-phosphorylation as the principle regulator of CAR activation and functions.
Xenobiotic-signal crosstalk mechanism: Upon activation by xenobiotics, CAR regulates genes differently from one another, conferring specificity to CAR-regulated gene expression. CAR acquires this specificity via crosstalk with cell signaling. We have identified various endogenous cell signals as the essential regulator of CAR activation and function: pituitary factor, p38 signaling, SGK2 signaling and the early response factor GADD45 (growth arrest and DNA-damage inducible 45. Given these findings, we are investigating the molecular mechanisms by which these signaling regulate CAR activation and functions.
CAR-mediated diseases: Chronic treatment with drugs, such as phenobarbital, is known to activate CAR and cause hepatocellular carcinoma (HCC) in rodents. We have now characterized GADD45 as a CAR target for phenobarbital promotion of HCC development: CAR interacts with GADD45 protein and this interaction inhibits phosphorylation of JNK1, thus repressing apoptosis and possibly promoting tumor genesis. 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) treatment is known to cause severe liver injury and proliferate postnatal hepatic progenitor oval cells. Utilizing CAR KO mice, we have determined that DDC activates CAR and this activation is essential for the developments of liver injury and oval cell proliferation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms and biological consequences of the nuclear receptor CAR activation
-
批准号:10004464
-
项目类别:
-
资助金额:$262.09万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Mechanisms and biological consequences of the nuclear receptor CAR activation
-
批准号:9352118
-
项目类别:
-
资助金额:$235.45万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Mechanism and biological consequences of the nuclear rec
-
批准号:7169993
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Pharmacogenetics Of Microsomal Steroid Hydroxylases
-
批准号:6508872
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Mechanisms and biological consequences of the nuclear receptor CAR activation
-
批准号:8929756
-
项目类别:
-
资助金额:$269.66万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Structural Study of Sulfotransferases
-
批准号:6227948
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Structural Biology of sulfotransferase and glycosyltrans
-
批准号:7328841
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Structural Biology of sulfotransferase and glycosyltransferase
-
批准号:7593958
-
项目类别:
-
资助金额:$38.81万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Mechanisms and biological consequences of the nuclear receptor CAR activation
-
批准号:8149056
-
项目类别:
-
资助金额:$384.44万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Mechanisms and biological consequences of the nuclear receptor CAR activation
-
批准号:8734114
-
项目类别:
-
资助金额:$235.22万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Activation Mechanism of the nuclear receptor CAR
-
批准号:7007473
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Structural Biology of sulfotransferase and glycosyltrans
-
批准号:6838567
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
DEVELOPMENTAL PHARMACOGENETICS OF MICROSOMAL STEROID HYDROXYLASES
-
批准号:6432408
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
DEVELOPMENTAL PHARMACOGENETICS OF MICROSOMAL STEROID HYDROXYLASES
-
批准号:6290069
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Structural Study Of Sulfotransferases
-
批准号:6508870
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Mechanisms and biological consequences of the nuclear receptor CAR activation
-
批准号:10253780
-
项目类别:
-
资助金额:$259.87万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Structural Study of Sulfotransferases
-
批准号:6432404
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Developmental Pharmacogenetics Of Microsomal Steroid Hyd
-
批准号:6681992
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Mechanism and biological consequences of the nuclear rec
-
批准号:7328859
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位:
Structural Biology of sulfotransferase and glycosyltrans
-
批准号:7007467
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:MASAHIKO NEGISHI
-
依托单位: